Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132713 | 0.86 | ALDH1A1 (0.52) | ADORA1RAB9ASRD5A2MAPK1 | |
| SCHEMBL8566481 | 0.83 | ALDH1A1 (0.56) | ADORA1MEN1KMT2APRKCZTDP1 | |
| SCHEMBL20280311 | 0.81 | ADORA1 (0.66) | ADORA1MEN1KMT2ARAB9APRKCZ | |
| SCHEMBL3974360 | 0.79 | PRKCZ (0.62) | ADORA1MEN1KMT2ARAB9APRKCZ | |
| SCHEMBL11862875 | 0.76 | ALDH1A1 (0.61) | KMT2A | |
| SCHEMBL944792 | 0.76 | ALDH1A1 (0.47) | MEN1KMT2APRKCZMAPK1HPGD | |
| SCHEMBL3972011 | 0.75 | PRKCZ (0.57) | ADORA1MEN1KMT2ARAB9APRKCZ | |
| SCHEMBL19986219 | 0.74 | MAPT (0.46) | ADORA1MEN1KMT2ARAB9ATDP1 | |
| SCHEMBL1919406 | 0.74 | ADORA1 (0.58) | ADORA1MEN1KMT2ARAB9APRKCZ | |
| SCHEMBL1920388 | 0.74 | ADORA1 (0.61) | ADORA1MEN1KMT2ARAB9APRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110914280-B | 6H-thieno [2,3-e ] [1,2,4] triazolo [3,4-c ] [1,2,4] triazab derivatives | 阿尤米制药公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20220356192-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-11-10 | — | — | US | disclosed |
| US-20220356192-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-11-10 | — | — | US | disclosed |
| US-11267822-B2 | BET bromodomain protein degraders with cleavable linkers | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-03-08 | — | — | US | disclosed |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2021-11-30 | — | — | US | disclosed |
| EP-3858837-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | The Regents of The University of Michigan (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858837-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | The Regents of The University of Michigan (US) | 2021-08-04 | — | — | EP | disclosed |
| US-11046709-B2 | Fused 1,4-diazepines as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046709-B2 | Fused 1,4-diazepines as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-06-29 | — | — | US | disclosed |
| EP-2326175-A2 | ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR | King Pharmaceuticals Research and Development Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20110053917-A1 | Allosteric Modulators of the A1 Adenosine Receptor | BARALDI PIER GIOVANNI | 2011-03-03 | — | — | US | disclosed |
| US-7897596-B2 | {2-Amino-4-[(4-(4-chlorophenyl)piperidin-1-yl)methyl]thiophen-3-yl}(4-chlorophenyl)methanone; analgesic, antidepressant; cardiac disease or disorder, neurological disease or injury, sleep disorder, epilepsy, neuropathic pain, angina | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7855209-B2 | Allosteric modulators of the A1 adenosine receptor | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20090281145-A1 | ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2009-11-12 | — | — | US | disclosed |
| WO-2009137782-A2 | ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-2081575-A2 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | King Pharmaceuticals Research and Development Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080125438-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008063984-A2 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080119460-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267822-B2 | BET bromodomain protein degraders with cleavable linkers | BRD4, BET1, BRWD1 | ADORA1 3740/4885MEN1 1308/4885KMT2A 170/4885 |
| US-20080119460-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885MEN1 4219/4885KMT2A 2529/4885 |
| US-20080125438-A1 | ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885MEN1 4219/4885KMT2A 2529/4885 |
| US-11046709-B2 | Fused 1,4-diazepines as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | ADORA1 3126/4885MEN1 1856/4885KMT2A 341/4885 |
| US-20110053917-A1 | Allosteric Modulators of the A1 Adenosine Receptor | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885MEN1 4442/4885KMT2A 2367/4885 |
| US-11186588-B2 | 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative | BRD4, BRD3, BRD2 | ADORA1 2726/4885MEN1 2870/4885KMT2A 43/4885 |
| US-20090281145-A1 | ALLOSTERIC ENHANCERS OF THE A1 ADENOSINE RECEPTOR | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885MEN1 4442/4885KMT2A 3013/4885 |
| US-20220356192-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | BRD4, BRD1, BET1 | ADORA1 2164/4885MEN1 1847/4885KMT2A 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.